You are here: Industry Insights > Pretomanid

News List

Trial reveals BPaL regimen for highly drug-resistant TB is effective even with reduced dose of linezolid expresspharma
July 16, 2021
This regimen reduces the treatment time for highly drug-resistant forms of TB from 18 months or longer to a six-month duration.
Mylan receives DCGI approval in India for TB drug, Pretomanid expresspharma
July 23, 2020
Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved in more than 40 years.
FDA Approves Pretomanid for Highly Drug-Resistant Forms of Tuberculosis drugs
August 15, 2019
Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) for treating some of the most drug-resistant forms of tuberculosis (TB).
TB Alliance, Mylan Announce Collaboration to Commercialize Pretomanid americanpharmaceuticalreview
April 19, 2019
Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).